TT-232
Also known as: Anticancer somatostatin heptapeptide, D-Phe-Cys-Tyr-D-Trp-Lys-Cys-Thr-NH2, TT232
Source TT-232 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
TT-232 is a synthetic heptapeptide analogue of somatostatin developed primarily as an anticancer agent. Unlike classical somatostatin analogues, it exerts potent antiproliferative and pro-apoptotic effects on tumor cells with minimal hormonal (antisecretory) activity. It has been investigated in preclinical and early clinical studies for solid tumors.
Mechanism of Action
Binds to somatostatin receptors (primarily SSTR4) and activates intrinsic apoptotic pathways in tumor cells; inhibits cell proliferation via caspase activation and modulation of tyrosine kinase signaling without significant endocrine effects.
Routes of Administration
Goals & Uses
- Induction of tumor cell apoptosisOncologyModerate
- Solid tumor treatmentOncologyLow
- Neuroendocrine tumor managementOncologyLow
- Antiangiogenic effectOncologyLow
Contraindications
- Severe hepatic impairmentOrganModerateLiver function concerns
- Known hypersensitivity to somatostatin analoguesAllergyHigh
- PregnancyPopulationHighPotential fetal risk or insufficient safety data
Adverse Effects
- HypoglycemiaMetabolicRareAbnormally low blood glucose
- Injection site reactionsLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
Drug Interactions
- Chemotherapeutic agentsModerate
- Insulin / Oral hypoglycemicsLow
Population Constraints
- Pediatric patientsAgeRelative
- Pregnant or lactating womenReproductiveRelative
- Patients with severe renal impairmentOrgan ImpairmentRelative
Regulatory Status
- European UnionInvestigationalPhase I/II clinical investigations conducted in Hungary; no EMA marketing authorization.
- United StatesInvestigationalNot FDA-approved; no IND filing publicly confirmed; research compound only.
- United KingdomUnknownNo MHRA approval; status mirrors EU investigational classification.
No approved indications in any major jurisdiction. Investigated in Phase I/II clinical trials in Europe (particularly Hungary). Not FDA-approved. Orphan or special research-use designations may apply in some contexts.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is TT-232?
TT-232 is a synthetic heptapeptide analogue of somatostatin developed primarily as an anticancer agent. Unlike classical somatostatin analogues, it exerts potent antiproliferative and pro-apoptotic effects on tumor cells with minimal hormonal (antisecretory) activity. It has been investigated in preclinical and early clinical studies for solid tumors.
What is TT-232 used for?
TT-232 is educationally associated with: Induction of tumor cell apoptosis, Solid tumor treatment, Neuroendocrine tumor management, Antiangiogenic effect. Educational only — not medical advice.
How is TT-232 administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of TT-232?
Reported adverse effects include: Hypoglycemia, Injection site reactions, Nausea, Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid TT-232?
Recorded contraindications: Severe hepatic impairment, Known hypersensitivity to somatostatin analogues, Pregnancy. Consult a qualified clinician before use.